These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34386573)

  • 1. The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation.
    Chantrarat T; Hauythan S
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100844. PubMed ID: 34386573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
    Yao X; Tangri N; Gersh BJ; Sangaralingham LR; Shah ND; Nath KA; Noseworthy PA
    J Am Coll Cardiol; 2017 Nov; 70(21):2621-2632. PubMed ID: 29169468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation.
    Shahzada TS; Guo CL; Lee APW
    Hong Kong Med J; 2022 Feb; 28(1):24-32. PubMed ID: 34737236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease.
    Li HJ; Lin SY; Lin FJ; Hung CS; Wang CC
    Curr Med Res Opin; 2021 Apr; 37(4):535-542. PubMed ID: 33538623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA
    Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation.
    Yao X; Inselman JW; Ross JS; Izem R; Graham DJ; Martin DB; Thompson AM; Ross Southworth M; Siontis KC; Ngufor CG; Nath KA; Desai NR; Nallamothu BK; Saran R; Shah ND; Noseworthy PA
    Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e006515. PubMed ID: 33012172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom.
    González Pérez A; Balabanova Y; Sáez ME; Brobert G; García Rodríguez LA
    Int J Cardiol; 2022 Apr; 352():165-171. PubMed ID: 35122912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation.
    Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
    Europace; 2021 Feb; 23(2):184-195. PubMed ID: 33063123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB
    Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.